AKTIS ONCOLOGY ANNOUNCES $175 MILLION …

Radiopharmaceutical firm Aktis Oncology raises $175M in Series B ...Aktis Oncology closes $175 million financing - Aktis

CouponFollow Extension

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION …

4 weeks from now

Radiopharmaceutical firm Aktis Oncology raises $175M in Series B ...Aktis Oncology closes $175 million financing - Aktis

aktisoncology.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series

4 weeks from now

Oct 1, 2024 · BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

biospace.com

$175
OFF

Radiopharmaceutical Firm Aktis Oncology Raises $175M In Series B ...

4 weeks from now

Oct 1, 2024 · Radiology Business

aktisoncology.com

$175
OFF

Aktis Oncology Closes $175 Million Financing - Aktis

4 weeks from now

Oct 1, 2024 · The Pharma Letter

aktisoncology.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

epicos.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

Sep 30, 2024 · Financing led by RA Capital Management and co-led by RTW Investments and Janus Henderson InvestorsProceeds to further advance the company's differentiated …

wpri.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Sep 30, 2024 · By Karen Roman Aktis Oncology said it raised $175 million in Series B financing, led by RA Capital Management, with RTW Investments and Janus Henderson Investors as co …

yahoo.com

$175
OFF

Brown Rudnick Assists Aktis Oncology In $175M Series B Financing

4 weeks from now

Sep 30, 2024 · Brown Rudnick acted as corporate and transactional counsel for biotech company Aktis Oncology in its oversubscribed and upsized $175 million Series B financing. Aktis …

brownrudnick.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, September 30, 2024-- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to …

vcaonline.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series B …

4 weeks from now

BOSTON, Sept. 30, 2024 -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad …

pappas-capital.com

$175
OFF

Series B - Aktis Oncology - 2024-09-30 - Crunchbase

4 weeks from now

Sep 30, 2024 · FinSMEs — Aktis Oncology Raises $175M in Series B Funding News • Sep 30, 2024 Venture Capital Access Online — AKTIS ONCOLOGY ANNOUNCES $175 MILLION …

crunchbase.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series B …

4 weeks from now

BOSTON, Sept. 30, 2024 -- (Healthcare Sales & Marketing Network) -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted …

salesandmarketingnetwork.com

FAQs about AKTIS ONCOLOGY ANNOUNCES $175 MILLION … Coupon?

What happened to aktis oncology?

BOSTON, Mass. – September 30, 2024 — Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. ...

How much did Aktis Oncology raise?

Aktis Oncology announced yesterday (August 25) that it has raised a series A extension financing of $84 million. This brings its total capital raised to date to $161 million. The Massachusetts-based company develops targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. ...

Has Aktis Oncology completed a Series A financing?

Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers, completed a $72 million Series A financing. ...

What is aktis oncology?

Aktis Oncology is a clinical stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. The company’s first of several pipeline programs targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. ...

Can Aktis Oncology treat solid tumors?

Aktis Oncology specializes in treating solid tumors using radiopharmaceutical therapies. The company's technology leverages the power of potent alpha radiation to more effectively destroy cancer cells. ...

When will aktis oncology present a presentation?

Aktis Oncology also announced that three abstracts, including one oral presentation, have been accepted for presentation at the upcoming in Barcelona, Spain, October 23-25, 2024. ...